SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending following the submission of an expanded deep-sea mining permit application under NOAA's newly streamlined regulatory process, signaling a significant step towards commercial recovery. This, coupled with an upcoming Congressional hearing featuring TMC's CEO and recent White House support for expediting critical mineral permits, has fueled strong bullish sentiment among investors who see deep-sea resources as a national security priority, with many discussing significant upside potential and a potential short squeeze.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ is generating significant buzz following its Memorandum of Understanding with the Government of Gujarat to establish a large-scale post-quantum semiconductor center in India, fueling expectations for future growth. Community members are actively discussing the company's critical role in quantum security, comparing it to other leading tech innovators as CEO Carlos Moreira engages with global leaders at Davos on the urgent need for post-quantum solutions. Despite persistent short interest, investors anticipate LAES will be a foundational player in securing the converging worlds of AI and IoT.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is actively trending as Chairman Ryan Cohen significantly increased his personal stake by purchasing an additional one million shares recently, reinforcing his commitment and challenging other CEOs to buy their company's stock. This substantial insider buying, coupled with another director's purchases, is igniting conversations among the community about potential for a renewed short squeeze and the company's long-term value, with many viewing it as a clear signal that the stock's bottom is established. Enthusiastic discussions highlight hopes for increased trading volume and a "round two" of significant price action, putting pressure on short positions amidst sustained retail interest.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals (SXTP) is seeing explosive trading volume after announcing a partnership to expand direct access to its ARAKODA malaria prevention drug for international travelers, coupled with news defining a potential $1.1 billion market for its babesiosis treatment. The low-float stock is drawing significant community attention, with traders discussing short-squeeze potential and chasing momentum amidst high volatility, though some express caution given the company's history of offerings.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is actively trending as the community anticipates a major hyperscaler tenant announcement for its expansive AI data center campus in West Texas, following a key acquisition and strategic partnership. Investors are intensely discussing the potential for a significant short squeeze and drawing comparisons to established data center infrastructure leaders, fueling strong bullish sentiment.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid community discussions regarding a potential US government agreement concerning Greenland's mineral rights, which many believe directly benefits CRML's Tanbreez rare earth project. Investors are actively discussing the company's strategic importance in establishing a non-China heavy rare earth supply chain, with a recent business update call providing additional insights into project funding and development plans.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant upward momentum following positive five-year follow-up data from its personalized cancer vaccine trial with Merck, demonstrating a notable reduction in melanoma recurrence. This news has ignited strong bullish sentiment within the community, with many highlighting the transformative potential of mRNA technology in oncology and anticipating further growth. The renewed focus on its diverse pipeline beyond initial vaccine developments is largely driving this increased investor interest.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as extreme cold weather forecasts are sending natural gas futures soaring, causing significant declines for this inverse leveraged ETF. The highly volatile natural gas market, often called the "widow maker," has many in the community debating whether to buy KOLD on this sharp dip, anticipating a short-term reversal once the cold snap subsides.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is generating significant buzz following FDA authorization for the use of its commercially manufactured GP2 drug product in the Phase III FLAMINGO-01 trial, marking a key de-risking milestone for its breast cancer immunotherapy. The community is sharply divided, with bulls pointing to the low float, high short interest, and ongoing insider buying as catalysts for a potential squeeze, while bears highlight a 'sell the news' pattern and anticipate further pullbacks.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings (RCAT) is trending following recent reports of significant revenue growth and notable institutional interest. The community is buzzing with anticipation ahead of its Needham conference presentation, where discussions are centered on potential major government contracts for its advanced drone and unmanned surface vessel (USV) technologies. This momentum, coupled with talks of short squeeze potential, positions RCAT as a key player in the rapidly expanding defense drone sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One...

Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1% - Time to Sell?

Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1% - Here's Why...

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire VANCOUVER, BC, Jan...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are currently covering the company...

Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy"

Wall Street Zen raised shares of Foghorn Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday...

BTIG Research Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Strong-Buy

BTIG Research raised shares of Foghorn Therapeutics to a "strong-buy" rating in a report on Thursday...

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

Platform Technologies Drive $211B Surge in Precision Cancer Treatment Platform Technologies Drive $211B Surge in Precision Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 11, 2025 Issued on behalf...

Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut Foghorn Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from Analysts

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat...

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Foghorn Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$6.11
Prev Close	$6.08
Open	$6.15
Dividend Yield	0.00%
50-Day Moving Average	$4.99
Beta	1.71
Avg. Volume	161,891.95
PE Ratio	-5.12

52-Week High	$6.95
52-Week Low	$2.94
Market Capitalization	$326.3M
EPS (Annual)	-$1.58
Price to Book	-3.83
Revenue Per Employee	$201,803.57
Enterprise Value/EBITDA	N/A

FHTX
Foghorn Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FHTX News

FHTXFoghorn Therapeutics Inc